Candida auris and COVID-19: A health threatening combination
نویسندگان
1 Department of Medical Mycology and Parasitology, School of Medicine, Babol University of Medical Sciences, Babol, Iran
2 Department of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
3 Invasive Fungi Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran
4 Department of Medical Mycology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
5 Invasive Fungi Research Center, Communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran
6 Molecular Medecine Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
7 Toxoplasmosis Research Center, Communicable Diseases, Institute, Mazandaran University of Medical Sciences, Mazandaran, Sari, Iran
8 Molecular Medecine Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
doi
10.18502/cmm.8.3.11211چکیده
Since its first emergence in December 2019, due to its fast distribution throughout the world, SARS-COV-2 become a global concern. With the extremely increased number of hospitalized patients, this situation provided a potential basis for the transmission of nosocomial infections. Candida auris is a multidrug-resistant pathogen with improved transmission dynamics and resistance traits. During the worldwide spread of COVID-19, cases or outbreaks of C. auris colonization or infection have been reported. Resistance to antifungal drugs has been observed in the causative agents of the majority of such cases. The focus in this review is on COVID-19-associated C. auris infections (case studies/outbreaks) and the pandemic's potential effect on antifungal drug resistance.
